论文部分内容阅读
我们应用巴曲酶治疗缺血性脑血管病时，曾发现该药能迅速控制频发的短暂脑缺血发作（ＴＩＡｓ）。本文目的是通过多中心随机、对照（与传统常规用药）研究，观察该药是否确实能速控频发ＴＩＡｓ。总数为５５例患者，根据ＴＩＡｓ患者的性别、年龄、严重程度，将患者随机分为巴曲酶治疗组及传统常规治疗组。入院后进行神经系统检查；并即予以治疗，观察及记录其发作终止之时间。结果为巴曲酶组有６８．９７％病人在３日内发作控制，而对照组仅１９．２３％，差异非常显著（Ｘ２＝１３．９２１，Ｐ＜０．０１）。表明巴曲酶确能迅速控制频发的ＴＩＡ。
When we used batroxobin to treat ischemic cerebrovascular disease, we found that it was able to rapidly control frequent episodes of transient ischemic attacks (TIAs). The purpose of this paper is to investigate whether this drug can indeed speed-control frequent TIAs through a multicenter, randomized, controlled (compared with conventional regimens) study. A total of 55 patients, according to gender, age and severity of TIAs patients, were randomly divided into batroxobin group and conventional treatment group. After admission, the neurological examination was performed; and the patients were treated to observe and record the time when the attack was terminated. As a result, 68.97% of patients in Batroxobin group were attacked within 3 days, while only 19.23% in control group, the difference was significant (X2 = 13.921, P <0.01). This indicates that batroxobin can rapidly control the frequent TIA.